font size
Sign in


The Rise in Drug Spending and
What It Means

Podcast: April 21, 2014

Reduced patent expirations, the introduction of the largest number of new drugs in a decade, and growing use of healthcare services helped increase total U.S. spending on drugs in 2013 by 3.2 percent, according to a new report from IMS Institute for Health Informatics. We spoke to the Institute’s Executive Director Murray Aitken about the report, what it tells us about the biopharmaceutical industry’s ability to bring innovative therapies to market, and the evolving debate of the cost and benefits of these new drugs.
Read More
Todays Stories
Podcast Personalizing Cancer Therapies with a Mouse

Joel Ackerman, CEO of Champions Oncology, discusses the personalization of cancer therapy, the benefits his company's mouse avatars provide, and how the same technology is being used to improve drug development.

By the numbers Intarcia Lands $200M for Disruptive Drug Delivery

Intarcia Therapeutics has raised another $200 million in private financing, which together with the $210 million round of equity and debt financing in November of 2012, puts the company in a strong position to complete a late-stage clinical trial and prepare to launch its once yearly diabetes treatment, and to build its pipeline.